NCT00413387 - Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®) | Biotech Hunter

Enrollment

219

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

August 31, 2005

Study Completion Date

October 31, 2005

Conditions

Bronchial Asthma

Interventions

DRUG

beclomethasone dipropionate plus formoterol fumarate combination

100mcg beclomethasone diproprionate plus 6 mcg formoterol

DRUG

budesonide plus formoterol combination

200mcg budesonide plus 6 mcg formoterol

Trial Locations (13)

Unknown

Ambulance For Paediatric and Pulmonology, Vienna

"Nzoz MedexPoradnia Alergologiczna", Bielsko-Biala

Centrum Uslug Medycznych, Krakow

Centrum Alergologii, Lodz

Prywatny Gabinet Lekarski, Lodz

Uniwersytet Medyczny, Lodz

Nzoz Lekarze Specjalisci, Wroclaw

Internal Medicine Department, Dniepropetrovsk State Medical Academy. City Clinical Hospital no. 4, Dniepropetrovsk

Institute of Therapy, Ukranian Academy of Medical Science. Pulmonological Departement, Kharkiv

Kharkov Regional Clinical Hospital. Pulmonological and Allergological Department, Kharkiv

Institute of Phthisiology and Pulmonology Academy of Medical Science of the Ukraine, Pulmonology Departement, Kiev

Institute of Phthisiology and Pulmonology Academy of Medical Science of the Ukraine. Department of Diagnostic, Therapy and Clinical Pharmacology of Lung Diseases, Kiev

Kiev Medical Academy of Postdiploma Education. Department of Medical Genetics, Clinical Immunology and Allergology, Kiev

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY